Sutro Biopharma STRO 深 沪
交易中 09-18 11:29:58 美东时间
0.8602
+0.008
+0.88%
华盛通- 最 高0.8799
- 今 开0.86
- 成交量 9.96万股
- 最 低 0.853
- 昨 收 0.8527
- 总市值 7265.37万
- 52周最高 4.60
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 0.5231
- 委 比 20.00%
- 总股本 8446.14万
- 历史最高 28.30
- 量 比 0.90
- 振 幅 3.15%
- 历史最低 0.5231
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Trump Warns Of $15 Trillion Investment Cancellation, Mcconnell Compares Tariff Era To 1930s And More: This Week In Politics
Trump warns of a $15T investment pullout, McConnell draws 1930s parallels, Musk gets snubbed at the White House, and Cuban cautions about political fallout.
09-07 17:01
Market Highs And Attractive Setups Ahead
S&P pushes to records, AVGO shows AI demand is real… The market keeps press...
09-05 23:04
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 28, 2025 /PRNewswire/ -- Federal budget cuts have put pressure on cancer research efforts in th...
08-28 22:44
中国石化、荣盛石化、恒力石化、江苏东方盛虹、万华化学、中石油、新凤鸣、恒逸石化、桐昆集团上榜2025全球化工50强！
（来源：能源知库） 近日，美国《化学与工程新闻》(C&EN)公布“2025年全球化工企业50强”。C&EN的全球化工企业50强排名一直是全球最大...
08-15 10:17
Wells Fargo Maintains Equal-Weight on Sutro Biopharma, Lowers Price Target to $3
Wells Fargo analyst Derek Archila maintains Sutro Biopharma (NASDAQ:STRO) with a Equal-Weight and lowers the price target from $4 to $3.
08-12 20:41
Sutro Biopharma Q2 EPS $(0.14) Beats $(0.45) Estimate, Sales $63.74M Beat $14.35M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.45) by 68.68 percent. This is a 76.27 percent increase over losses of $(0.59) per share from
08-08 04:42
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma reported strong progress in advancing its ADC pipeline, including planning to initiate a clinical trial for STRO-004, a Tissue Factor-targeting ADC, in late 2025. The company expanded preclinical data across its pipeline and entered a collaboration with the FDA to improve regulatory standards. Greg Chow was appointed as Chief Financial Officer. The company had $205.1 million in cash and expects runway into early 2027. Revenue for ...
08-07 20:30
President Trump Posts On Truth Social: 'THE AUGUST FIRST DEADLINE IS THE AUGUST FIRST DEADLINE — IT STANDS STRONG, AND WILL NOT BE EXTENDED. A BIG DAY FOR AMERICA!!!'
https://trumpstruth.org/statuses/32275
07-30 19:51
Lifeway Foods Acknowledges ISS Recommendation to Reject Dissident Campaign
MORTON GROVE, Ill., July 29, 2025 /PRNewswire/ -- Lifeway Foods, Inc. (NASDAQ: LWAY), a leading U.S. supplier of kefir and fermented probiotic products, today announced that Institutional Sh...
07-30 05:35
